Evidence map›Paper›PMID 32258239›Full record

ArticleMovement disorders clinical practice2020

Levodopa Equivalent Dose Conversion Factors: An Updated Proposal Including Opicapone and Safinamide.

Sebastian Schade, Brit Mollenhauer, Claudia Trenkwalder

Registry-linked trialAbstract read
In one paragraph

Article in Movement disorders clinical practice, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05635409 (STEM-PD Trial), which is not on this map. Cited by 221 papers.

0numbers the graph read from it
0cells of the map it votes in
221citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05635409 phase1active not recruitingnot on this mapstarted 2022, after this paper: background citation

STEM-PD Trial: A Multicentre, Single Arm, First in Human, Dose-escalation Trial, Investigating the Safety and Tolerability of Intraputamenal Transplantation of Human Embryonic Stem Cell Derived Dopaminergic Cells for Parkinson's Disease (STEM-PD Product)

TypeinterventionalSponsorRegion SkaneRan2022 to 2027Enrolled8ConditionsParkinson DiseaseArmsSTEM-PD
3 · Its place in the literature

Who cites it

221 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Effect of Opicapone on Levodopa Pharmacokinetics in Patients with Fluctuating Parkinson's Disease.Movement disorders : official journal of the Movement Disorder Society · 2022
    Trial
  14. Article
  15. Observational
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

161 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Sebastian SchadeDepartment of Clinical Neurophysiology University Medical Center Göttingen Göttingen Germany.ORCID https://orcid.org/0000-0002-6316-6804
Brit MollenhauerParacelsus-Elena-Klinik Klinikstr. 16, 34128 Kassel Germany.
Claudia TrenkwalderParacelsus-Elena-Klinik Klinikstr. 16, 34128 Kassel Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

LEDlevodopa equivalent doseopicaponesafinamide

Identifiers

PMID32258239
PMCPMC7111582

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.